

**Claims:**

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

1.-45. (Canceled)

46. (Previously presented) A method for treating a cancerous tumor, comprising:  
implanting a wholly-implantable electroporation device wholly within a body,  
wherein said wholly-implantable electroporation device includes a drug reservoir and  
operative control circuitry both disposed within a housing for said wholly-implantable  
electroporation device;

delivering a drug to the body and proximate the cancerous tumor via a fluid  
conduit coupled to the drug reservoir;

delivering from the wholly-implantable electroporation device, at least one  
electrical pulse across at least a portion of the cancerous tumor, wherein said at least  
one electrical pulse produces an electrical field strength of from about 700 V/cm to  
about 1500 V/cm and said electrical pulse has a pulse width of from about 50  
microseconds to about 200 microseconds; and

detecting a qRs complex from an electrogram of the body and synchronizing the  
delivering of the at least one electrical pulse with the qRs complex..

47. (Previously presented) The method of claim 46, further comprising:

sensing at least one biological parameter and providing a sense signal based on  
the biological parameter; and

conveying said parameter to said operative control circuitry disposed within the  
housing of the device.

48. (Original) The method of claim 47, further comprising controlling delivery of the at least one electrical pulse based on the sense signal.

49. (Cancelled)

50. (Original) The method of claim 46, further comprising measuring impedance across a portion of the cancerous tumor and comparing the impedance to a threshold impedance value.

51. (Original) The method of claim 50, further comprising suspending delivery of additional electrical pulses based on a result of comparing the impedance to the threshold impedance value.

52. (Original) The method of claim 46, wherein delivering the drug to the body comprises delivering the drug via an external drug delivery apparatus.

53. (Cancelled)

54. (Original) The method of claim 46, further comprising increasing a temperature of the body in the vicinity of the cancerous tumor prior to delivering the at least one electrical pulse.

55. (Original) The method of claim 54, wherein increasing the temperature of the body in the vicinity of the cancerous tumor comprises delivering a high frequency stimulus with the electroporation device.

56. (Original) The method of claim 46, further comprising programming the electroporation device to deliver a particular therapy profile.

57. (Original) The method of claim 56, wherein programming the electroporation device occurs after implantation.

58. (Previously presented) A method for treating cancer, comprising:

implanting a wholly-implantable electroporation device in a body, the wholly-implantable electroporation device operable to selectively electroporate tissue within the body using at least one lead having at least one wholly implantable therapy electrode associated therewith; and locating the at least one wholly implantable therapy electrode in or proximate a cancerous tumor;

applying a high frequency stimulus in the vicinity of the cancerous tumor with the at least one wholly-implantable first therapy electrode, thereby raising a temperature in the vicinity of the cancerous tumor;

delivering a drug to the body in the vicinity of the cancerous tumor; and delivering, with the wholly-implantable electroporation device, at least one electrical pulse in the vicinity of the cancerous tumor, wherein said at least one electrical pulse produces an electrical field strength of from about 700 V/cm to about 1500 V/cm and has a pulse width of from about 50 microseconds to about 200 microseconds; and

detecting a qRs complex from an electrogram of the body and synchronizing the delivering of the at least one electrical pulse with the qRs complex.

59. (Original) The method of claim 58, further comprising sensing the temperature in the body and providing a sense signal based on the temperature.

60. (Cancelled)

61. (Original) The method of claim 58, further comprising measuring impedance across a portion of the cancerous tumor and comparing the impedance to a threshold impedance value.

62. (Original) The method of claim 61, comprising suspending delivery of additional electrical pulses based on a result of comparing the impedance to the threshold impedance value.

63. (Original) The method of claim 58, wherein delivering the drug to the body comprises delivering the drug through a drug catheter coupled to a housing of the electroporation device, the drug catheter in fluid communication with a drug reservoir located within the housing.

64. (Original) The method of claim 58, wherein delivering the drug to the body comprises delivering the drug via an external drug delivery apparatus.

65. (Original) The method of claim 58, wherein the cancerous tumor is a breast carcinoma.

66. (Original) The method of claim 58, wherein the cancerous tumor is a osteosarcoma.

67. (Original) The method of claim 58, wherein delivering the at least one electrical pulse comprises delivering about four to about eight electrical pulses.

68.-83. Cancelled